Skip to content

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Sionna Therapeutics, Inc. Common Stock logo
Sionna Therapeutics, Inc. Common StockSION
0.0×

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0
Free cash flow-$12.4M

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Current ratio2.6×-0.9×

Where this comes from

Calculated from Achieve Life Sciences’s reported figures.

Based on the most recent quarter.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's debt-to-equity?
Achieve Life Sciences (ACHV) reported debt-to-equity of 0.5× in Q1 2026.
How has Achieve Life Sciences's debt-to-equity changed year-over-year?
Achieve Life Sciences's debt-to-equity increased by 315.9% year-over-year, from 0.1× to 0.5×.
What is the long-term trend for Achieve Life Sciences's debt-to-equity?
Over 4 years (2020 to 2025), Achieve Life Sciences's debt-to-equity has grown at a 149.8% compound annual growth rate (CAGR), from 0× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.